Crespo-Rodriguez AM, Sanz Sanz J, Freites D, Rosales Z, Abasolo L, Arrazola J. Role of diagnostic imaging in psoriatic arthritis: how, when, and why. Insights Imaging. 2021;12:121.

Article  PubMed  PubMed Central  Google Scholar 

Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465–79.

Article  PubMed  PubMed Central  Google Scholar 

Coates LC, van der Horst-Bruinsma IE, Lubrano E, et al. Sex-specific differences in patients with psoriatic arthritis: a systematic review. J Rheumatol. 2023;50:488–96.

Article  PubMed  Google Scholar 

Gossec L, Walsh JA, Michaud K, et al. Women with psoriatic arthritis experience higher disease burden than men: findings from a real-world survey in the United States and Europe. J Rheumatol. 2023;50:192–6.

Article  PubMed  Google Scholar 

Duruöz MT, Gezer HH, Nas K, et al. Gender-related differences in disease activity and clinical features in patients with peripheral psoriatic arthritis: a multi-center study. Jt Bone Spine. 2021;88(4):105177.

Article  Google Scholar 

Eder L, Thavaneswaran A, Chandran V, Gladman DD. Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. Ann Rheum Dis. 2013;72(4):578–82.

Article  PubMed  Google Scholar 

Kojanova M, Fialova J, Cetkovska P, et al. Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic. Dermatol Ther. 2021;34(2):e14849.

Article  PubMed  Google Scholar 

Nas K, Capkin E, Dagli AZ, et al. Gender specific differences in patients with psoriatic arthritis. Mod Rheumatol. 2017;27(2):345–9.

Article  PubMed  Google Scholar 

Tarannum S, Leung YY, Johnson SR, et al. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol. 2022;18:513–26.

Article  PubMed  Google Scholar 

Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42:1460–8.

Article  CAS  PubMed  Google Scholar 

Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DD. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis. 2006;65(4):478–81.

Article  CAS  PubMed  Google Scholar 

Geijer M, Lindqvist U, Husmark T, et al. The swedish early psoriatic arthritis registry 5-year followup: substantial radiographic progression mainly in men with high disease activity and development of dactylitis. J Rheumatol. 2015;42:2110–7.

Article  CAS  PubMed  Google Scholar 

Hojgaard P, Ballegaard C, Cordtz R, et al. Gender differences in biologic treatment outcomes-a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers. Rheumatology (Oxford). 2018;57:1651–60.

Article  PubMed  Google Scholar 

Passia E, Vis M, Coates LC, et al. Sex-specific differences and how to handle them in early psoriatic arthritis. Arthritis Res Ther. 2022;24:22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park J, Rutter C, Avalos-Reyes E, et al. Impact of sex on medication adherence in members with rheumatoid arthritis, psoriatic arthritis, or systemic lupus erythematosus [abstract]. Arthritis Rheumatol. 2024;76(suppl 9). https://acrabstracts.org/abstract/impact-of-sex-on-medication-adherence-in-members-with-rheumatoid-arthritis-psoriatic-arthritis-or-systemic-lupus-erythematosus/. Accessed 20 Dec 2024.

Pina Vegas L, Penso L, Sbidian E, Claudepierre P. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS). RMD Open. 2023;9:e003570.

Article  PubMed  PubMed Central  Google Scholar 

Rida MA, Lee KA, Chandran V, Cook RJ, Gladman DD. Persistence of biologics in the treatment of psoriatic arthritis: data from a large hospital-based longitudinal cohort. Arthritis Care Res (Hoboken). 2023;75(10):2174–81.

Article  CAS  PubMed  Google Scholar 

Eder L, Mylvaganam S, Pardo Pardo J, et al. Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis. Lancet Rheumatol. 2023;5:e716–27.

Article  CAS  PubMed  Google Scholar 

Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011;147:429–36.

Article  CAS  PubMed  Google Scholar 

Janssen Biotech, Inc. TREMFYA (guselkumab) [package insert]. U.S. Food and Drug Administration website. Revised March 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761061s024lbl.pdf. Accessed 23 Apr 2025.

Janssen Biotech, Inc. TREMFYA (guselkumab) [package insert]. European Medicines Agency website. Revised May 2025. https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf/. Accessed 20 May 2025.

Mease P, Ritchlin C, Coates L, et al. Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: results through week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study. Abstract #0010. EULAR 2025; June 11–14, Barcelona, Spain.

Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1115–25.

Article  CAS  PubMed  Google Scholar 

Ritchlin CT, Deodhar A, Boehncke WH, et al. Multidomain efficacy and safety of guselkumab through 1 year in patients with active psoriatic arthritis with and without prior tumor necrosis factor inhibitor experience: analysis of the phase 3, randomized, placebo-controlled DISCOVER-1 study. ACR Open Rheumatol. 2023;5(3):149–64.

Article  PubMed  PubMed Central  Google Scholar 

McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheum. 2022;74(3):475–85.

Article  CAS  Google Scholar 

Ritchlin CT, Mease PJ, Boehncke WH, et al. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clin Rheumatol. 2024;43(8):2551–63.

Article  PubMed  PubMed Central  Google Scholar 

Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81(3):359–69.

Article  CAS  PubMed  Google Scholar 

Gottlieb AB, McInnes IB, Rahman P, et al. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naive patients with active psoriatic arthritis. RMD Open. 2023;9(1):e002789.

Article  PubMed  PubMed Central  Google Scholar 

Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126–36.

Article  CAS  PubMed  Google Scholar 

Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727–35.

Article  CAS  PubMed  Google Scholar 

Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811–8.

Article  PubMed  Google Scholar 

Cella D, Wilson H, Shalhoub H, et al. Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. J Patient Rep Outcomes. 2019;3:30.

Article  PubMed  PubMed Central  Google Scholar 

Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011;38(11):2461–5.

Article  PubMed  Google Scholar 

van der Heijde D, Sharp J, Wassenberg S, Gladman DD. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis. 2005;64(Suppl 2):ii61–4.

Article